Mnemosyne Pharmaceuticals is developing novel therapeutics targeting the NMDA receptor to treat neuropsychiatric disorders. Mnemosyne targets subtypes of the NMDA receptor, the brain's master switch for learning and memory. The company's lead programs are focused on schizophrenia, Rett syndrome, and depression.
news
Jan 25-30, 2014 Frank Menniti speaks on panel about Rett syndrome at 47th Winter Conference on Brain Research >>
July 2, 2013 Mnemosyne Pharmaceuticals Inc. Completes $6.0 Million Expansion of Series A Financing >>
Feb 20, 2012 Mnemosyne announces entering into a drug discovery collaboration with Jubilant Biosys Limited, Bangalore, India. >>
Feb 16, 2012 Mnemosyne announces Series A fi nancing of $5.4M, as reported in BioWorld Today. >>
Mnemosyne is the Greek goddess of memory and rememberance. The painting in the background above is by Gabriel Dante Rosetti, c. 1875.